CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Clovis Oncology, Inc.

5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
United States

Full Time Employees468

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. MahaffyCo-Founder, CEO, Pres & Exec. Director1.14MN/A1963
Dr. Gillian C. Ivers-ReadCo-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations689.09kN/A1954
Mr. Daniel W. MuehlExec. VP of Fin., Principal Financial Officer & Principal Accounting Officer605.38kN/A1964
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPMExec. VP of Clinical, Preclinical Devel. & Pharmacovigilance and Chief Medical OfficerN/AN/A1968
Mr. Paul Edward GrossChief Compliance Officer, Exec. VP, Gen. Counsel & Sec.N/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company's product candidates include lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors; and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; collaboration and license agreement with Les Laboratoires Servier; a clinical collaboration with Bristol-Myers Squibb Company; a partnership with Foundation Medicine, Inc; a diagnostic collaboration with Myriad Genetics, Inc.; and a research collaboration with Alkermes plc to evaluate Alkermes ALKS 4230, an investigational engineered interleukin-2 variant immunotherapy in combination with rucaparib and lucitanib. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Corporate Governance

Clovis Oncology, Inc.’s ISS Governance QualityScore as of March 1, 2019 is 8. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.